Exosomal MiR-221 Targets DNM3 to Induce Tumor Progression and Temozolomide Resistance in Glioma

Overview

Journal J Neurooncol

Publisher Springer

Date 2016 Nov 13

PMID 27837435

Citations 71

Authors

Jian-Kai Yang

Ji-Peng Yang

Jing Tong

Shi-Yuan Jing

Bo Fan

Feng Wang

Guo-Zhu Sun

Bao-Hua Jiao

Affiliations

Soon will be listed here.

Abstract

MicroRNA is an important regulator of glioblastoma. This study aims at validating microRNA-221 (miR-221) as a biomarker for glioblastoma, and understanding how miR-221 regulates glioblastoma progression. Using clinical samples, miR-221 expression was analyzed by quantitative reverse-transcriptase PCR (qPCR). SHG-44 cells were treated with anti-miR-221 or U87MG-derived exosomes followed by monitoring changes in cell viability, migration and temozolomide (TMZ) resistance. Bioinformatics approach was used to identify targets of miR-221. The interaction between miR-221 and its target, DNM3 gene, was studied with dual-luciferase reporter assay, Spearman's correlation analysis, and western blotting. To verify that RELA regulates miR-221 expression, RELA-expressing vector or shRNA was introduced into SHG-44 cells and its effect on miR-221 expression was monitored. Both tissue-level and exosomal miR-221 expression increased with glioma grades. In SHG-44 cells, downregulating miR-221 expression inhibited cell proliferation, migration, and TMZ resistance, whereas incubation with U87MG-derived exosomes exerted tumor-promoting effects. DNM3 gene is a target of miR-221. RELA induced miR-221 expression. In glioma, elevated miR-221 expression is a biomarker for glioma. DNM3 is a target of miR-221 and RELA regulates miR-221 expression. The RELA/miR-221 axis is a target for glioma diagnosis and therapy.

Citing Articles

Unlocking the therapeutic potential of tumor-derived EVs in ischemia-reperfusion: a breakthrough perspective from glioma and stroke.

Hao Z, Guan W, Wei W, Li M, Xiao Z, Sun Q J Neuroinflammation. 2025; 22(1):84.

PMID: 40089793 DOI: 10.1186/s12974-025-03405-7.

Exploring the roles and clinical potential of exosome-derived non-coding RNAs in glioma.

Jin P, Bai X IBRO Neurosci Rep. 2025; 18:323-337.

PMID: 40034544 PMC: 11872630. DOI: 10.1016/j.ibneur.2025.01.015.

Exosomes in the Chemoresistance of Glioma: Key Point in Chemoresistance.

Guo X, Piao H, Sui R J Cell Mol Med. 2025; 29(4):e70401.

PMID: 39950738 PMC: 11826829. DOI: 10.1111/jcmm.70401.

Impact of hypoxia on the molecular content of glioblastoma-derived exosomes.

Di Giulio S, Carata E, Muci M, Mariano S, Panzarini E Extracell Vesicles Circ Nucl Acids. 2024; 5(1):1-15.

PMID: 39698411 PMC: 11648508. DOI: 10.20517/evcna.2023.52.

Glioma-Derived Exosomes and Their Application as Drug Nanoparticles.

Mastantuono S, Manini I, Di Loreto C, Beltrami A, Vindigni M, Cesselli D Int J Mol Sci. 2024; 25(23).

PMID: 39684236 PMC: 11641060. DOI: 10.3390/ijms252312524.

References

Ciafre S, Galardi S, Mangiola A, Ferracin M, Liu C, Sabatino G . Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005; 334(4):1351-8. DOI: 10.1016/j.bbrc.2005.07.030. View

DeAngelis L . Brain tumors. N Engl J Med. 2001; 344(2):114-23. DOI: 10.1056/NEJM200101113440207. View

Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H . Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res. 2014; 6(4):391-401. PMC: 4113501. View

Zheng Q, Peskoe S, Ribas J, Rafiqi F, Kudrolli T, Meeker A . Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate. 2014; 74(16):1655-62. PMC: 4205269. DOI: 10.1002/pros.22883. View

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

Zhang C, Kang C, You Y, Pu P, Yang W, Zhao P . Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol. 2009; 34(6):1653-60. DOI: 10.3892/ijo_00000296. View

Chen L, Zhang J, Han L, Zhang A, Zhang C, Zheng Y . Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep. 2011; 27(3):854-60. DOI: 10.3892/or.2011.1535. View

Hao J, Zhang C, Zhang A, Wang K, Jia Z, Wang G . miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. Oncol Rep. 2012; 27(5):1504-10. DOI: 10.3892/or.2012.1652. View

Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y . Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther. 2013; 6:1417-24. PMC: 3797647. DOI: 10.2147/OTT.S51913. View

10.

Zhang Z, Chen C, Guo W, Zheng S, Sun Z, Geng X . DNM3 Attenuates Hepatocellular Carcinoma Growth by Activating P53. Med Sci Monit. 2016; 22:197-205. PMC: 4725618. DOI: 10.12659/msm.896545. View

11.

Orth J, McNiven M . Dynamin at the actin-membrane interface. Curr Opin Cell Biol. 2003; 15(1):31-9. DOI: 10.1016/s0955-0674(02)00010-8. View

12.

Louis D . Molecular pathology of malignant gliomas. Annu Rev Pathol. 2007; 1:97-117. DOI: 10.1146/annurev.pathol.1.110304.100043. View

13.

Pereira D, Rodrigues P, Borralho P, Rodrigues C . Delivering the promise of miRNA cancer therapeutics. Drug Discov Today. 2012; 18(5-6):282-9. DOI: 10.1016/j.drudis.2012.10.002. View

14.

Zhang C, Zhang J, Zhang A, Shi Z, Han L, Jia Z . MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer. 2010; 9:229. PMC: 2939570. DOI: 10.1186/1476-4598-9-229. View

15.

Ujifuku K, Mitsutake N, Takakura S, Matsuse M, Saenko V, Suzuki K . miR-195, miR-455-3p and miR-10a( *) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett. 2010; 296(2):241-8. DOI: 10.1016/j.canlet.2010.04.013. View

16.

Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H . Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One. 2014; 9(10):e109347. PMC: 4183700. DOI: 10.1371/journal.pone.0109347. View

17.

Calin G, Croce C . MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006; 66(15):7390-4. DOI: 10.1158/0008-5472.CAN-06-0800. View

18.

Omuro A, DeAngelis L . Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310(17):1842-50. DOI: 10.1001/jama.2013.280319. View

19.

Yang C, Robbins P . The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol. 2011; 2011:842849. PMC: 3235485. DOI: 10.1155/2011/842849. View

20.

Yau T, Wu C, Dong Y, Tang C, Ng S, Chan F . microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer. 2014; 111(9):1765-71. PMC: 4453736. DOI: 10.1038/bjc.2014.484. View